Nuvation Bio (NUVB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary

Pipeline overview and clinical progress

• Three main programs: IBTROZI (ROS1 inhibitor for NSCLC, approved July last year), safusidenib (IDH1 inhibitor for brain tumors in pivotal studies), and a Drug-Drug Conjugate (DDC) platform with updates expected later this year.

• IBTROZI has shown a 90% response rate and 50-month duration of response, the highest among ROS1 TKIs, and is the only ROS1 drug in an adjuvant trial, expanding its market by 30%.

• Safusidenib demonstrates superior efficacy over vorasidenib in low-risk, low-grade gliomas and shows promise in high-grade settings, with pivotal readouts expected in 2027 and 2029.

• DDC platform is being updated after learnings from earlier assets, with a new program announcement planned for later this year.

Competitive landscape and regulatory milestones

• IBTROZI received FDA breakthrough designation for 1st and 2nd line, priority review, and rapid approval, while Nuvalent's NVL-520 received breakthrough only for 3rd line and standard review.

• IBTROZI outperforms NVL-520 in response rates and intracranial efficacy, especially in real-world, difficult-to-treat populations.

• NCCN guidelines now recommend ROS1 agents over IO chemo for ROS1 lung cancer and recently included IBTROZI for CNS disease due to its robust intracranial response rate.

Market opportunity and financial outlook

• U.S. ROS1 lung cancer market estimated at 3,000 new cases/year; with current pricing and duration of response, revenue stacking could reach $4–5 billion annually, especially as first-line use grows.

• RNA testing could further expand the market by 30%, and first-line patient share has increased from 30% to over 50% in three quarters.

• Short-term sales are growing 35% quarter-over-quarter, with consensus annual sales around $130 million and potential to exceed if trends continue.

• Safusidenib's market potential is significant due to long survival in IDH1 gliomas, with revenue stacking possibly 4–5x IBTROZI's duration.

• Over $530 million in cash provides operational runway to profitability, supporting ongoing and future clinical programs.